"Today's headline was "Coverage Indicates 3X Greater Revenue Potential for Brilacidin Oral Rinse".
That seemed to refer to this, from the text: "Most glaring was the analyst’s model projecting a course of treatment for Galera’s GC4419 at $15,400 (net). The price point is viewed as in-line with other supportive care treatments. We conservatively modeled our Brilacidin Oral Rinse pricing at $5,000 for a course of treatment, leaving plenty of room for upward adjustment while providing the opportunity for a decisive pricing advantage."
I can point to the analysts support for that $15,400 cost number for Galera: "We assume a course of therapy consists of 35 doses, administered over seven weeks, at a gross price of $550/dose, or $15,400 per course of therapy, net of applicable discounts and rebates (we assume 20%)." So one IV infusion a day for 5 days a week at $550/infusion.
"Does the "3X Greater Revenue Potential for Brilacidin Oral Rinse" come from an assumption that there is room for a tripling of the previously unknown price per dose of B-OM."
My thoughts, for your reflection. They(ipix) stated:
We conservatively modeled our Brilacidin Oral Rinse pricing at $5,000 for a course of treatment, leaving plenty of room for upward adjustment while providing the opportunity for a decisive pricing advantage." I believe it likely boils down to pricing vs costs. If Galera costs are much higher, particularly due to administration costs((iv supervision(over paid healthcare ceo's/underlings), etc, money grubbers)/administration/documentation)), in today's age of fumble, stumble, and trip, it takes not long to escalate things, costs included.
"I need it dumbed down for me. Care to give it a try?"